Gene Therapy for Fabry Disease to Advance to Phase 2 Clinical Trials – AJMC.com Managed Markets Network
|
Gene Therapy for Fabry Disease to Advance to Phase 2 Clinical Trials
AJMC.com Managed Markets Network If eventually approved, AVR-RD-01 could revolutionize the treatment of FD; currently, the standard of care for the disease is enzyme replacement therapy that involves lifelong, biweekly infusions of the high-cost drug Fabrazyme (agalsidase beta), which … |
